BravoVax Granted 10 National Patents

Recently, 10 patents, “A Combination Vaccine of RSV-PCV and its Preparation Process” and 9 more patents, independently developed and applied by BravoVax, have been granted authorization by the National Intellectual Property Administration, China, which has further enlarged our intellectual property pool.

‌Ever since the establishment of BravoVax, the company has focused on the innovation of science and technology, and protection of IPR. The granting of these 10 new patents not only expands the company’s patent portfolio, but also shows its strong innovation ability and sharp technology foresight. BravoVax will continue making endeavors to enhance R&D strength in vaccine innovation, employ in-house intellectual property into the project, and further expand the protection of its platform technology for our large portfolio of human vaccines, taking the lead in the highly competitive international market.